Sinotherapeutics Inc. (SHA:688247)

Sinotherapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	512.84	511.08	299.41	246.69	314.38	316
Other Revenue	0.4	0.54	0.46	0.87	1.09	3.16
Revenue	513.23	511.62	299.87	247.56	315.47	319.16
Revenue Growth (YoY)	26.07%	70.61%	21.13%	-21.53%	-1.16%	129.84%
Cost of Revenue	263.81	246.11	133.5	68.44	70.44	61.41
Gross Profit	249.42	265.51	166.37	179.12	245.03	257.75
Selling, General & Admin	56.28	55.25	43.93	43.9	45.71	56.75
Research & Development	76.56	84.92	74.01	76.02	103.63	75.8
Other Operating Expenses	3.86	2.19	3.03	-0.63	0.77	2.02
Operating Expenses	137.89	146.02	122.07	120.91	149.94	135.08
Operating Income	111.53	119.48	44.3	58.21	95.1	122.66
Interest Expense	-0	-0	-0.04	-0.21	-0.23	-
Interest & Investment Income	16.4	16.38	17.45	25.02	5.66	26.16
Currency Exchange Gain (Loss)	0.1	2.07	1.26	5.52	-4	-12.08
Other Non Operating Income (Expenses)	0.11	-0.07	-0.06	-0.05	0.43	-0.59
EBT Excluding Unusual Items	128.14	137.86	62.91	88.48	96.95	136.15
Gain (Loss) on Sale of Investments	-	-	-	-	0.46	-
Gain (Loss) on Sale of Assets	-0.57	-0.59	-0.11	0.12	-0.02	0.04
Asset Writedown	-0.99	-0.92	-1.62	-0.85	-0.1	-0.09
Other Unusual Items	7.27	5.74	4.8	9.73	51.72	6.22
Pretax Income	133.85	142.08	65.99	97.48	149.01	142.32
Income Tax Expense	14.72	14.38	4.92	4.54	14.1	19.02
Net Income	119.13	127.7	61.07	92.93	134.92	123.3
Net Income to Common	119.13	127.7	61.07	92.93	134.92	123.3
Net Income Growth	28.88%	109.09%	-34.28%	-31.12%	9.42%	2558.14%
Shares Outstanding (Basic)	458	456	470	422	409	408
Shares Outstanding (Diluted)	458	456	470	422	409	408
Shares Change (YoY)	-1.96%	-2.92%	11.22%	3.32%	0.21%	-
EPS (Basic)	0.26	0.28	0.13	0.22	0.33	0.30
EPS (Diluted)	0.26	0.28	0.13	0.22	0.33	0.30
EPS Growth	31.46%	115.39%	-40.91%	-33.33%	10.00%	2900.00%
Free Cash Flow	12.52	35.3	-26	-103.15	129.77	171.7
Free Cash Flow Per Share	0.03	0.08	-0.06	-0.24	0.32	0.42
Dividend Per Share	0.062	0.062	0.041	0.062	-	-
Dividend Growth	-6.06%	51.22%	-33.87%	-	-	-
Gross Margin	48.60%	51.90%	55.48%	72.35%	77.67%	80.76%
Operating Margin	21.73%	23.35%	14.77%	23.51%	30.14%	38.43%
Profit Margin	23.21%	24.96%	20.37%	37.54%	42.77%	38.63%
Free Cash Flow Margin	2.44%	6.90%	-8.67%	-41.67%	41.13%	53.80%
EBITDA	128.81	137.79	67.38	83.75	121.21	135.27
EBITDA Margin	25.10%	26.93%	22.47%	33.83%	38.42%	42.38%
D&A For EBITDA	17.28	18.3	23.08	25.55	26.12	12.61
EBIT	111.53	119.48	44.3	58.21	95.1	122.66
EBIT Margin	21.73%	23.35%	14.77%	23.51%	30.14%	38.43%
Effective Tax Rate	11.00%	10.12%	7.45%	4.66%	9.46%	13.36%
Revenue as Reported	513.23	511.62	299.87	247.56	315.47	319.16
Advertising Expenses	-	0.77	0.42	0.69	-	0.08

Source: S&P Global Market Intelligence. Standard template. Financial Sources.